Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Childhood Acute Lymphoblastic Leukemia
NCT00165087Phase 3Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 1996
- Primary completion
- Sep 2006
- Modality
- Small Molecules, Replacement Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of dexrazoxane, asparaginase escherichia coli, crisantaspase recombinant in acute lymphoblastic leukemia (ALL), sponsored by Dana-Farber Cancer Institute. Started Jan 1996; status: terminated.
02
Drugs
dexrazoxaneasparaginase escherichia colicrisantaspase recombinant
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00165087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00165087.